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events were considered, reflecting the year 2015. All outcomes were discounted 
at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment 
cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, 
€ 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 
9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and it was cost-
effective compared to ETA generating an incremental cost-effectiveness ratio 
(ICER) of € 26,848/QALY gained (willingness-to-pay threshold: € 34,000). CZP was 
less effective (-0.082 QALYs) but less costly (-€ 29,015) than IFX, whereas it was 
more effective (+0.046 QALYs) and more costly (+€ 3,383) than GOL. CZP and GOL 
provided the lowest ICERs versus CC amongst comparators. Regarding nr-axSpA, 
the total treatment cost with CC, ADA and CZP was: € 4,754, € 33,748 and € 34,625; 
and QALYs were: 10.412, 10.681 and 10.948. The ICER of CZP versus CC and ADA 
was € 55,726 and € 3,289, respectively; CZP dominated ADA. ConClusions: CZP 
may be considered a cost-effective option with respect to the alternative axSpA 
therapies in Greece.
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objeCtives: The aim of this study is to analyze healthcare costs of osteoporosis 
and to build a economic model cost-effectiveness of pharmacological intervents 
based on real world data Methods: The cost analysis was conducted taking each 
healthcare service into account during the study period (2005-2008). A hypotheti-
cal scenario based on the real-life available evidence was constructed. The mean 
level of adherence to populate the hypothetical scenario of full adherence was set 
at MPR > 80%. The model was built by adding a step value to the real-world adher-
ence of each subject so that the subject shifted to the hypotetical scenario of full 
adherence. Cost-effectiveness of full adherence compared to real-world adherence 
was expressed in terms of ICER and the number of fractures avoided was set as an 
effectiveness unit of measure. Results: The mean annual healthcare cost was 
€ 247.44 per not fractured patient and € 1,044.85 per fractured patient. The eco-
nomic model showed that the average cost of medical treatments in case of optimal 
adherence per patient/year would increase from € 88.73 in real-world adherence 
to € 125.52 in full adherence. The rising costs are compensated by a reduction in 
number of fractures, decreasing by 65%. In this scenario, also the total yearly costs 
related hospitalizations would decrease from € 319,379 in real-word adherence to 
€ 110,917 in full adherence. The ICER, expressed in terms of cost/fracture avoided 
equals € 821 (cost that the NHS should invest to avoide a fracture) ConClusions: 
This study demonstrated the potential of the use of existing data sources to evalu-
ate appropriateness of drug use. Drugs cost money to buy, but if we use them in 
an appropriate way we can also save costs in other areas. In particular enhancing 
adherence to medication may lead to reductions in the number of patients requir-
ing hospitalization.
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objeCtives: We assessed the cost-effectiveness of placing apremilast, a new oral 
treatment, before anti-TNFα in the treatment pathway in psoriatic arthritis (PsA) 
patients who had failed ≥ 2 conventional DMARDs, from a Scottish payer perspec-
tive. Methods: A lifetime Markov cohort model was developed comparing 2 treat-
ment sequences: apremilast followed by adalimumab followed by etanercept vs. 
adalimumab followed by etanercept. Non-responders moved to the next line of 
therapy, or best supportive care (BSC) as last treatment line. Response was assessed 
using the Psoriatic Arthritis Response Criteria (PsARC) at the end of trial periods, 
ranging from 12-16 weeks. A 16.5% annual dropout rate was assumed for each 
drug. Efficacy inputs were obtained from a network meta-analysis and trial results. 
Utilities were estimated from the Health Assessment Questionnaire (HAQ) and 
Psoriasis Area and Severity Index response using a published regression equation. 
The HAQ score was assumed to progress in BSC. Unit costs were sourced from the 
British National Formulary, NHS reference costs, and other published sources, with 
apremilast priced at £550/4-week cycle. A 3.5% annual discount rate was applied to 
costs and quality-adjusted life-years (QALYs). Results: The apremilast arm pro-
vided an additional 2.49 years with a PsARC response and an additional 0.78 QALYs. 
Total time spent on anti-TNFα agents was reduced by 0.33 years, and time spent 
in BSC was reduced by 2.79 years. Under base-case assumptions, placing apremi-
last before anti-TNFα was more effective and less costly (incremental QALYs: 0.71; 
cost: £11,695), resulting in a cost of £16,507/QALY gained. Structural and param-
eter assumptions were tested in sensitivity analyses, which indicated results were 
sensitive to several parameters (e.g., HAQ increase on BSC, discount rates, cost of 
BSC). ConClusions: Placing apremilast before anti-TNFα agents is cost-effective 
in PsA treatment. Apremilast has been recommended for use in Scotland for the 
management of PsA patients.
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objeCtives: Assess the model structure, treatment sequence and outcome in con-
temporary cost effectiveness analysis (CEA) studies in the US and UK. Methods: 
Studies on conventional and biologic Disease-modifying anti-rheumatic drugs 
PMS58
coST-effecTiveneSS of aBaTacePT coMPaRed To adaliMUMaB in iTaly 
BaSed on a head-To-head oUTcoMeS STUdy in RheUMaToid aRThRiTiS
Gaultney J1, Nappi C2, Benucci M3, Iannazzo S4, Sion K1, Alemao E5, Sabater J6
1Mapi Group, Houten, The Netherlands, 2Bristol Myers Squibb S.r.l., Roma, Italy, 3Rheumatology 
Unit Hospital, Florence, Italy, 4SIHS Health Economics Consulting, Torino, Italy, 5Bristol-Myers 
Squibb, Princeton, NJ, USA, 6Bristol-Myers Squibb, Madrid, Spain
objeCtives: Rheumatoid arthritis (RA) is a chronic, inflammatory disorder lead-
ing to disability and reduced quality of life. Effective treatment with biologic 
disease-modifying antirheumatic drugs (bDMARDs) is a significant economic 
burden on the Italian healthcare system. Economic models comparing bDMARDs 
are commonly based on indirect treatment comparisons. The Abatacept ver-
sus Adalimumab Comparison in Biologic-Naive RA Subjects with Background 
Methotrexate (AMPLE) trial was a head-to-head randomized study comparing 
subcutaneous abatacept to adalimumab, both combined with methotrexate, in 
RA patients. This study evaluated the cost-effectiveness of abatacept relative to 
adalimumab for RA patients based on AMPLE from the Italian National Health 
Service (NHS) perspective. Methods: A decision tree was designed to compare 
the costs and health benefits of abatacept and adalimumab in a cohort of 1,000 
patients over a 2-year time horizon. Efficacy, safety and concomitant drug use 
was based on AMPLE. Health benefits were based on stringent efficacy criteria: 
American College of Rheumatology (ACR)70/90 response and the health assess-
ment questionnaire disability index (HAQ-DI). Unit costs were estimated from pub-
lished public prices for 2014. Univariate sensitivity analyses assessed uncertainty 
of model inputs. Results: Abatacept dominated adalimumab in the treatment of 
RA patients with its higher effectiveness and lower costs over 2 years. Total health 
benefits were higher for abatacept compared to adalimumab, with 18, 63 and 
53 additional patients achieving ACR70, ACR90 and HAQ-DI response. Total costs 
favoured abatacept over adalimumab, with cost-savings of € 237,246. Cost-savings 
were due to lower costs for bDMARDs (-€ 262,527), treatment-related serious AEs 
(-€ 121,764), and local injection site reactions (-€ 14,047). Sensitivity analyses show 
that the cost-savings are robust while the difference in health benefits is sensi-
tive to parameter variation. ConClusions: For the Italian NHS, abatacept is less 
costly and more effective than adalimumab for RA patients according to ACR70, 
ACR 90, and HAQ-DI outcomes based on the AMPLE trial.
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objeCtives: Psoriatic arthritis (PsA) treatment may involve use of biologic injec-
tions/infusions. Apremilast was recently approved for treatment of adults with 
active PsA. Oral apremilast is priced significantly lower than biologics. Published 
comparative healthcare cost data are lacking for PsA patients receiving apremilast 
vs. biologics in a real-world care setting. We compared healthcare costs among 
PsA patients initiating apremilast or a biologic from the US managed care perspec-
tive. Methods: Adults with ≥ 2 diagnosis codes for PsA (ICD-9:696.0) were selected 
from the 2014-2105 MarketScan Commercial and Medicare Supplemental database. 
The first prescription date was defined as the index date; patients had to be continu-
ously enrolled for ≥ 6 months pre-index and ≥ 3 months post-index. To ensure new 
patient starts, biologic users had to be treatment-naïve to index medication in the 
pre-index period, although prior use of another biologic was not reason for exclu-
sion. Healthcare costs (2014 US$) were defined as the sum of pharmacy+medical 
service costs (e.g., inpatient, outpatient [including intravenous infusions], emer-
gency, and all other services [laboratory, radiology, other ancillary services]). Results, 
expressed as cost/patient/month, were reported separately for disease-specific PsA 
costs. Results: 469 (apremilast) and 1,120 (biologics) patients met inclusion cri-
teria; mean enrollment post-index was 5.6 and 6.5 months, respectively. Baseline 
demographics were balanced between cohorts, except mean age (apremilast: 52.9y; 
biologics: 49.8y; P< 0.001) and mean Charlson Comorbidity Index score (apremilast: 
0.8; biologics: 0.7; P= 0.016). Mean monthly costs for initiating apremilast vs. biologics 
were: all healthcare, $3,198 vs. $4,247 (P< 0.001); all PsA-related healthcare, $2,301 vs. 
$3,447 (P< 0.001), including PsA-related pharmacy, $2,095 vs. $2,617 (P< 0.001); PsA-
related inpatient, $43 vs. $48 (P= 0.776); PsA-related emergency, $4 vs. $10 (P= 0.456); 
PsA-related outpatient, $155 vs. $767 (P< 0.001); and all other PsA-related services, 
$4 vs. $5 (P= 0.748). ConClusions: Apremilast cost less than biologics, with aver-
age savings of ≈$1,000/patient/month based on lower PsA-related pharmacy and 
PsA-related outpatient costs.
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objeCtives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) in 
the treatment of axial spondyloarthritis (axSpA), including ankylosing spondy-
litis (AS) and non-radiographic axSpA (nr-axSpA), from a Greek payer perspec-
tive. Methods: A Markov model was locally adapted to evaluate the health effects 
and associated costs of CZP, adalimumab (ADA), infliximab (IFX), etanercept (ETA), 
golimumab (GOL) and conventional care (CC) in AS; and CZP, ADA and CC in nr-
axSpA. The model incorporated clinical practice patterns and the natural history 
of axSpA, following patients from treatment initiation to death. Efficacy data from 
randomized trials of comparators were included in a meta-analysis of a mixed 
treatment comparison analysis. The assessment period for AS and nr-axSpA was 
24 and 12 weeks, respectively. Direct costs for treating axSpA (medication acqui-
sition, administration, monitoring, and healthcare visits) and managing adverse 
